Natural Capsules Limited is now listed on both
BSE and NSE, with a current market capitalization of approximately ₹261 crore.
The NSE listing aligns with NCL’s strategic vision to access a larger pool of
investors, increase liquidity, and improve corporate governance standards.
Additionally, (NCL) has achieved a significant industry milestone by becoming
the second-largest Hard Gelatine Capsules manufacturer in India. This
achievement underscores the company’s operational excellence and commitment to
innovation.
The NSE listing will enable NCL to enhance
transparency, boost corporate governance, and improve credibility. These
factors contribute to strengthening investor confidence and reinforcing the
company’s reputation in the capital markets.
The NSE listing offers NCL multiple benefits,
including increased liquidity through greater trading volumes and improved
investor access. It allows broader engagement from institutional and retail
investors while strengthening transparency and credibility through enhanced
corporate governance. Additionally, it provides comprehensive market coverage
across equity, fixed income, and derivative securities, making NCL more visible
and attractive to potential investors.
Mr. Sunil Mundra, Managing Director of NCL,
stated: “This is a major milestone in NCL’s 32-year journey. The NSE listing
will significantly boost our growth trajectory, allowing us to reach a much
wider investor base and raise higher volumes of risk capital to undertake
larger projects.”
Mr. Raj Kishore Prasad, Chief Financial
Officer (CFO) of NCL, commented: “Our NSE listing is a transformational step
that enhances liquidity and opens up new avenues for capital raising. It
strengthens our commitment to transparency, governance, and market expansion,
ultimately benefiting all stakeholders.”
While NCL continues to evaluate new business
growth opportunities, acquisitions, and strategic investments, no concrete
decisions have been made at this stage. However, the NSE listing plays a
crucial role in supporting the company’s long-term growth plans.
With this listing, NCL is poised for a
promising future, reinforcing its leadership position in the pharmaceutical and
biotech industry while delivering sustained value to its investors.